Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.67 |
| ▸ | SELP | P16109 | 1/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.37 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL719429 | 1.00 | ABCB1 (0.67) | ABCB1SELPSIRT2SIRT1PTPN1 | |
| SCHEMBL718305 | 0.94 | ABCB1 (0.68) | ABCB1SELPSIRT2SIRT1PTPN1 | |
| SCHEMBL16448288 | 0.94 | ABCB1 (0.68) | ABCB1SELPSIRT2SIRT1PTPN1 | |
| SCHEMBL3824112 | 0.94 | ABCB1 (0.60) | ABCB1SELPSIRT2SIRT1PTPN1 | |
| SCHEMBL13679697 | 0.92 | ABCB1 (0.62) | ABCB1SELPSIRT2SIRT1PTPN1 | |
| SCHEMBL4442578 | 0.90 | ABCB1 (0.53) | ABCB1SELPSIRT2SIRT1PTPN1 | |
| SCHEMBL4442576 | 0.90 | ABCB1 (0.53) | ABCB1SELPSIRT2SIRT1PTPN1 | |
| SCHEMBL13679678 | 0.86 | ABCB1 (0.63) | ABCB1SELPSIRT2SIRT1PTPN1 | |
| SCHEMBL13679672 | 0.86 | ABCB1 (0.56) | ABCB1SELPSIRT2SIRT1PTPN1 | |
| SCHEMBL13679656 | 0.82 | ABCB1 (0.70) | ABCB1PTPN1BRAFMAPTNOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1221847-B1 | METHODS OF ENHANCING CHEMOTHERAPY | TAIJI BIOMEDICAL INC (US) | 2009-03-25 | — | — | EP | claimed |
| US-20070203215-A1 | Methods & Compositions For Enhancing Pharmaceutical Treatments | TAIJI BIOMEDICAL, INC. (US) | 2007-08-30 | — | — | US | claimed |
| US-9023845-B2 | Compositions and methods for treating lysosomal disorders | NEURALTUS PHARMACEUTICALS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20150044193-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED a-SYNUCLEIN FUNCTION | NEURALTUS PHARMACEUTICALS, INC. | 2015-02-12 | — | — | US | disclosed |
| US-20130012539-A1 | Compositions and Methods for Treating Lysosomal Disorders | THE HOSPITAL FOR SICK CHILDREN (CA) | 2013-01-10 | — | — | US | disclosed |
| US-8252789-B2 | Compositions and methods for treating lysosomal disorders | NEURALTUS PHARMACEUTICALS, INC. (US) | 2012-08-28 | — | — | US | disclosed |
| US-20120052053-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED ALPHA-SYNUCLEIN FUNCTION | THE PARKINSON'S INSTITUTE | 2012-03-01 | — | — | US | disclosed |
| EP-2361089-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED -SYNUCLEIN FUNCTION | Parkinson's Institute (US) | 2011-08-31 | — | — | EP | disclosed |
| US-20090163500-A1 | COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL DISORDERS | THE HOSPITAL FOR SICK CHILDREN (CA) | 2009-06-25 | — | — | US | disclosed |
| EP-1221847-B1 | METHODS OF ENHANCING CHEMOTHERAPY | TAIJI BIOMEDICAL INC (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20070203215-A1 | Methods & Compositions For Enhancing Pharmaceutical Treatments | TAIJI BIOMEDICAL, INC. (US) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120052053-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED ALPHA-SYNUCLEIN FUNCTION | SNCA, PARK7, NLN | ABCB1 3788/4885SELP 2342/4885SIRT2 2173/4885 |
| US-20090163500-A1 | COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL DISORDERS | GAA, GBA1, LIPA | ABCB1 1406/4885SELP 4856/4885SIRT2 1076/4885 |
| US-20150044193-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED a-SYNUCLEIN FUNCTION | SNCA, PARK7, NLN | ABCB1 3602/4885SELP 2292/4885SIRT2 2457/4885 |
| US-20130012539-A1 | Compositions and Methods for Treating Lysosomal Disorders | GAA, GBA1, LIPA | ABCB1 1406/4885SELP 4856/4885SIRT2 1076/4885 |
| US-20070203215-A1 | Methods & Compositions For Enhancing Pharmaceutical Treatments | TUBB3, TUBB1, TUBB2A | ABCB1 21/4885SELP 410/4885SIRT2 1995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.